Cue Biopharma Inc. (CUE)
NASDAQ: CUEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CUE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $34.69M
- EPS (TTM)
- -$27.80
- Dividend yield
- None
- 52-week range
- 2.83 – 45.50
- Day range
- 4.05 – 4.90
- Volume / Avg
- 1.26M / 567.02K
- Beta
- —
- Shares outstanding
- 8.36M
52-week range
CUE stock today
Cue Biopharma (CUE) closed at $4.15 on Nov 20, down 7.78% (-$0.35), versus the S&P 500's 3.70% decline. Volume was 2.2x the average at 1.26M shares, a sign of unusually heavy trading. Shares are 90.9% below their 52-week high of $45.50, set on Jul 10, 2026 and 46.6% above the 52-week low of $2.83, near the bottom of the past year's range.
CUE is down 54.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 76.8%. Cue Biopharma has posted a net loss over the last twelve months (EPS of -$27.80), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cue Biopharma
Company profileCue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Shao-Lee Lin M.D., Ph.D.
- Headquarters
- Boston, MA
- Employees
- 29
- IPO year
- 2018
- Website
- cuebiopharma.com
Financial highlights
Full financialsIn fiscal 2025, Cue Biopharma generated $27.5 million in revenue, up 195.7% from fiscal 2024, its 3rd consecutive year of revenue growth. Cue Biopharma reported a net loss of $26.6 million, compared with a loss of $40.7 million a year earlier. Operating margin was -96.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $27.47M | $9.29M | $5.49M | $1.25M | $14.94M |
| Growth | +195.75% | +69.16% | +340.96% | -91.67% | +373.68% |
| Net income | $-26.60M | $-40.67M | $-50.73M | $-53.01M | $-44.16M |
| EPS (diluted) | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 |
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$88.00+2020.48%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-4.42 vs $-4.04
- Surprise
- -9.41%
CUE news
All CUE newsCue Biopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GRCEGrace Therapeutics Inc. | 1.71 | -0.58% | $35.97M | vs CUE |
| VERUVeru Inc. | 1.94 | -8.06% | $33.08M | vs CUE |
| ATNMActinium Pharmaceuticals Inc. (Delaware) | 1.05 | -1.87% | $33.01M | vs CUE |
| HYFTMindWalk Holdings Corp. | 0.6844 | -14.27% | $32.56M | vs CUE |
| PLRXPliant Therapeutics Inc. | 0.5951 | -4.02% | $36.89M | vs CUE |
| SDEVStablecoin Development Corporation | 0.50 | -10.30% | $36.90M | vs CUE |
| GRDXGridAI Technologies Corp. | 3.16 | -8.41% | $32.44M | vs CUE |
| FLNAFilana Therapeutics Inc. | 0.6413 | +14.52% | $32.26M | vs CUE |
Indexes, lists and sector
Cue Biopharma stock FAQ
What is Cue Biopharma's stock price today?
CUE last traded at $4.15 as of Nov 20, 4:00 PM EST, down 7.78% on the day. Prices are delayed at least 15 minutes.
Does Cue Biopharma pay a dividend?
No. Cue Biopharma does not currently pay a regular cash dividend.
Who is Cue Biopharma's CEO?
Dr. Shao-Lee Lin M.D., Ph.D. is the chief executive officer of Cue Biopharma Inc., which has about 29 employees.
Has CUE ever split its stock?
Yes. The most recent CUE stock split was a 1-for-30 split on Apr 24, 2026.
What is the CUE 52-week high?
The 52-week high for CUE is $45.50 and the 52-week low is $2.83. The stock is currently 90.9% below its high.